Evidence map›Paper›PMID 42707326›Full record

ArticleFrontiers in oncology2026

SFRT alleviates symptoms associated with bulky advanced cancer: a retrospective single-center cohort analysis.

Haiqin Zhang, Jian Zhang, Chen Su, Yanming Wang, Chuanyong Liu, Yan Dou, Jie Liu, Weichong Zhao, Sen Liu, Changsheng Cong and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Haiqin ZhangDepartment of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Jian ZhangDepartment of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Chen SuDepartment of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Yanming WangDepartment of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Chuanyong LiuDepartment of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Yan DouDepartment of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Jie LiuDepartment of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Weichong ZhaoDepartment of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Sen LiuDepartment of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Changsheng CongDepartment of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Jin YuDepartment of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Meili SunDepartment of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective/background: To evaluate the impact of Spatially Fractionated Radiation Therapy (SFRT) on symptomatic relief and survival outcomes in patients with large-volume tumors. Methods: A total of 60 cancer patients who received SFRT between February 2023 and May 2025 were analyzed in this retrospective study. Collected data comprised demographic characteristics, as well as follow-up information on symptomatic response, best overall response, survival duration, and treatment-related adverse events. Results: By the end of the median follow-up duration of 15.8 months (3.8-30.8 months), 91.7% (55/60) of patients showed symptomatic relief. Follow-up imaging was available for 51 patients, showing tumor regression in 45 cases (6 showed increased volume after treatment). According to RECIST 1.1 criteria, 17 patients achieved Partial response (PR), 32 had Stable disease (SD), and 2 experienced Progressive disease (PD). The Overall response rate (ORR) was 33.3%, and the Disease control rate (DCR) was 96.1%. The median Overall survival (OS) was 7.6 months (95% CI: 4.3-10.9). Univariate analysis identified that a Biologically effective dose at the Vertex (BED-Vertex) ≥ 88 Gy was significantly associated with treatment response (P = 0.020). All adverse events were mild to moderate in severity, no grade 3 or higher toxicities were observed. Conclusion: SFRT appeared to be effective with limited toxicities for bulky tumors. BED-Vertex is a significant predictor of response in univariate analysis, suggesting that a strategy of safe BED escalation could enhance palliative efficacy.

Indexed as

bulky tumorimmunotherapylattice radiotherapyspatially fractionated radiation therapystereotactic central/core ablative radiation therapy

Identifiers

PMID42707326
PMCPMC13547061

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.